Related Experiment Videos
Serotonin transporter gene polymorphism and antidepressant response
1Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Neuroreport
|February 23, 2000
Summary
Genetic variations in the serotonin transporter (5-HTT) gene influence antidepressant response. Specific 5-HTT gene polymorphisms, particularly in intron 2 and the promoter region, predict better outcomes for depression treatment with SSRI medications.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Molecular Biology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are common antidepressants.
- The serotonin transporter (5-HTT) gene plays a crucial role in serotonin reuptake.
- Genetic variations in the 5-HTT gene may affect individual responses to SSRI treatment.
Purpose of the Study:
- To investigate the association between 5-HTT gene allelic polymorphisms and antidepressant response.
- To determine if specific 5-HTT genotypes predict treatment outcomes for depression.
Main Methods:
- Genotyping of 120 depressed patients and 252 controls using polymerase chain reaction (PCR).
- Analysis of allelic polymorphisms in the second intron and promoter regions of the 5-HTT gene.
- Assessment of patient response to 6 weeks of fluoxetine or paroxetine treatment.
Main Results:
- No association found between depression diagnosis and 5-HTT polymorphisms.
- Patients with homozygous l/l genotype in intron 2 showed significantly better SSRI response (p < 0.0001).
- Patients with homozygous s/s genotype in the promoter region also demonstrated improved response (p = 0.0074).
- Absence of the l/l allele in intron 2 strongly predicted non-response (83.3%).
Conclusions:
- Allelic variations in the 5-HTT gene are related to SSRI drug response in depressed Korean patients.
- Specific 5-HTT genotypes may serve as predictive biomarkers for antidepressant efficacy.